{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T12:07:02Z","timestamp":1794485222703,"version":"4.9.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medical-Scientific Fund of the Mayor of the federal capital Vienna","award":["19086"],"award-info":[{"award-number":["19086"]}]},{"name":"Medical-Scientific Fund of the Mayor of the federal capital Vienna","award":["21165"],"award-info":[{"award-number":["21165"]}]},{"name":"Physician Researcher Pathway Scholarship of the Medical University of Vienna"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health Grant","doi-asserted-by":"crossref","award":["R01-NS119231"],"award-info":[{"award-number":["R01-NS119231"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"name":"DOD Grant","award":["CA201129P1"],"award-info":[{"award-number":["CA201129P1"]}]},{"name":"\u201cForschungsgesellschaft f\u00fcr Cerebrale Tumore\u201d"},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund - FWF","doi-asserted-by":"crossref","award":["T 906-B28"],"award-info":[{"award-number":["T 906-B28"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Initiative Krebsforschung-Grant"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      <jats:italic>BRAF<\/jats:italic>\n                      -altered pediatric high-grade gliomas (pHGG) harbor a dismal prognosis. Although targeted therapy with BRAF and MEK inhibitors provides initial benefit, resistance emerges rapidly in clinical practice indicating an urgent need for improved therapeutic strategies. As\n                      <jats:italic>BRAF<\/jats:italic>\n                      mutations frequently co-occur with homozygous\n                      <jats:italic>CDKN2A\/B<\/jats:italic>\n                      loss, we investigated CDK4\/6 inhibition as a rational therapeutic strategy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Using\n                      <jats:italic>BRAF-<\/jats:italic>\n                      mutant cell and human-to-organoid transplant (HOT) models, we assessed the impact of CDK4\/6 and MEK inhibitors as mono- or combination therapies on viability, apoptosis, senescence, and molecular signaling. Activation of signaling pathways in primary and recurrent matched samples pre- and post-combined MEK and BRAF treatment was examined by RNA sequencing. In vivo efficacy was evaluated in orthotopic and subcutaneous patient-derived xenograft (PDX) models, as well as in one clinical case.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      <jats:italic>BRAF<\/jats:italic>\n                      -mutant,\n                      <jats:italic>CDKN2A\/B<\/jats:italic>\n                      -deficient pHGGs displayed strong sensitivity to the CDK4\/6 inhibitor abemaciclib in addition to the MEK inhibitor trametinib. These tumors were particularly vulnerable to combined abemaciclib and trametinib treatment, which induced senescence and apoptosis, and uniquely suppressed mTOR activity. Both HOT and PDX models exhibited tumor regression, prolonged survival and sustained response even after therapy discontinuation. These effects were accompanied by a decreased mesenchymal-like cellular phenotype, as indicated by lower CD44 expression and a shift toward a more rounded cell morphology. Interestingly, trametinib- and dabrafenib post-treatment samples exhibited further increase in CD44 levels, along with upregulation of PI3K and hypoxia signaling, indicating therapy-associated reinforcement of mesenchymal transition.\n                    <\/jats:p>\n                    <jats:p>The combination of trametinib and ribociclib was translated into clinical application, by showing good response of a patient with BRAF-altered and therapy-refractory pHGG.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Our study demonstrated enhanced and prolonged effects of combined CDK4\/6 and MEK inhibition in\n                      <jats:italic>BRAF<\/jats:italic>\n                      \/\n                      <jats:italic>CDKN2A<\/jats:italic>\n                      -co-altered recurrent pHGG. We further provide evidence that the aggressive mesenchymal cell compartment is particularly targeted by this treatment combination, warranting further preclinical and clinical investigation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-026-03725-3","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T13:44:51Z","timestamp":1778939091000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Co-targeting CDK4\/6 and MEK reverses mesenchymal transition in therapy-refractory BRAF-altered pediatric high-grade glioma"],"prefix":"10.1186","volume":"45","author":[{"given":"Lisa","family":"Mayr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Mager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Gabler-Pamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Kirchhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Freund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kallen","family":"Schwark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benison","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Machreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Senfter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mia","family":"Neum\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibylle","family":"Madlener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Laemmerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Bruckner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carola N.","family":"Jaunecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Robl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romina","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Schueler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Peyrl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amedeo A.","family":"Azizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Dorfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"Roessler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Spiegl-Kreinecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Haberler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniello","family":"Federico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apurva","family":"Gopisetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudrun","family":"Schleiermacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan M.","family":"Pfister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Geoerger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Chesler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Vassal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Kool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonhard","family":"M\u00fcllauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Koschmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Gojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"L\u00f6tsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,16]]},"reference":[{"key":"3725_CR1","doi-asserted-by":"publisher","first-page":"1038096","DOI":"10.3389\/fimmu.2022.1038096","volume":"13","author":"P Aggarwal","year":"2022","unstructured":"Aggarwal P, Luo W, Pehlivan KC, et al. Pediatric versus adult high grade glioma: Immunotherapeutic and genomic considerations. Front Immunol. 2022;13:1038096. https:\/\/doi.org\/10.3389\/fimmu.2022.1038096.","journal-title":"Front Immunol"},{"key":"3725_CR2","doi-asserted-by":"publisher","first-page":"1074726","DOI":"10.3389\/fonc.2022.1074726","volume":"12","author":"M Capogiri","year":"2023","unstructured":"Capogiri M, De Micheli AJ, Lassaletta A, et al. Response and resistance to BRAFV600E inhibition in gliomas: Roadblocks ahead? Front Oncol. 2023;12:1074726. https:\/\/doi.org\/10.3389\/fonc.2022.1074726.","journal-title":"Front Oncol"},{"key":"3725_CR3","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1093\/nop\/npaf061","volume":"12","author":"B Geoerger","year":"2025","unstructured":"Geoerger B, Moreno L, Bouffet E, et al. Dabrafenib in pediatric patients with BRAF V600 mutation\u2013positive high-grade glioma: Results from a phase 1\/2a single-arm study. Neurooncol Pract. 2025;12:1099\u2013111. https:\/\/doi.org\/10.1093\/nop\/npaf061.","journal-title":"Neurooncol Pract"},{"key":"3725_CR4","doi-asserted-by":"publisher","first-page":"5174","DOI":"10.1200\/JCO.23.00558","volume":"41","author":"DR Hargrave","year":"2023","unstructured":"Hargrave DR, Terashima K, Hara J, et al. Phase II Trial of Dabrafenib Plus Trametinib in Relapsed\/Refractory BRAF V600\u2013Mutant Pediatric High-Grade Glioma. J Clin Oncol. 2023;41:5174\u201383. https:\/\/doi.org\/10.1200\/JCO.23.00558.","journal-title":"J Clin Oncol"},{"key":"3725_CR5","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1093\/neuonc\/noae074","volume":"26","author":"P O\u2019Hare","year":"2024","unstructured":"O\u2019Hare P, Cooney T, de Blank P, et al. Resistance, rebound, and recurrence regrowth patterns in pediatric low-grade glioma treated by MAPK inhibition: A modified Delphi approach to build international consensus-based definitions-International Pediatric Low-Grade Glioma Coalition. Neuro Oncol. 2024;26:1357\u201366. https:\/\/doi.org\/10.1093\/neuonc\/noae074.","journal-title":"Neuro Oncol"},{"key":"3725_CR6","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s11060-024-04672-9","volume":"168","author":"D Kocher","year":"2024","unstructured":"Kocher D, Cao L, Guiho R, et al. Rebound growth of BRAF mutant pediatric glioma cells after MAPKi withdrawal is associated with MAPK reactivation and secretion of microglia-recruiting cytokines. J Neurooncol. 2024;168:317\u201332. https:\/\/doi.org\/10.1007\/s11060-024-04672-9.","journal-title":"J Neurooncol"},{"key":"3725_CR7","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.cell.2019.06.024","volume":"178","author":"C Neftel","year":"2019","unstructured":"Neftel C, Laffy J, Filbin MG, et al. An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. Cell. 2019;178:835\u2013e84921. https:\/\/doi.org\/10.1016\/j.cell.2019.06.024.","journal-title":"Cell"},{"key":"3725_CR8","doi-asserted-by":"publisher","first-page":"9654","DOI":"10.3390\/ijms21249654","volume":"21","author":"S Haase","year":"2020","unstructured":"Haase S, Nu\u00f1ez FM, Gauss JC, et al. Hemispherical Pediatric High-Grade Glioma: Molecular Basis and Therapeutic Opportunities. Int J Mol Sci. 2020;21:9654. https:\/\/doi.org\/10.3390\/ijms21249654.","journal-title":"Int J Mol Sci"},{"key":"3725_CR9","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s40478-019-0775-6","volume":"7","author":"L Gabler","year":"2019","unstructured":"Gabler L, L\u00f6tsch D, Kirchhofer D, et al. TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAFV600E\/TERT promoter double-mutated glioma. Acta Neuropathol Commun. 2019;7:128. https:\/\/doi.org\/10.1186\/s40478-019-0775-6.","journal-title":"Acta Neuropathol Commun"},{"key":"3725_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-018-5120-0","volume":"18","author":"L Fraz\u00e3o","year":"2018","unstructured":"Fraz\u00e3o L, do Carmo Martins M, Nunes VM, et al. BRAF V600E mutation and 9p21: CDKN2A\/B and MTAP co-deletions - Markers in the clinical stratification of pediatric gliomas. BMC Cancer. 2018;18:1\u201310. https:\/\/doi.org\/10.1186\/s12885-018-5120-0.","journal-title":"BMC Cancer"},{"key":"3725_CR11","doi-asserted-by":"publisher","first-page":"693104","DOI":"10.3389\/fonc.2021.693104","volume":"11","author":"MA George","year":"2021","unstructured":"George MA, Qureshi S, Omene C, et al. Clinical and Pharmacologic Differences of CDK4\/6 Inhibitors in Breast Cancer. Front Oncol. 2021;11:693104. https:\/\/doi.org\/10.3389\/fonc.2021.693104.","journal-title":"Front Oncol"},{"key":"3725_CR12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41571-023-00840-4","volume":"21","author":"L Morrison","year":"2023","unstructured":"Morrison L, Loibl S, Turner NC. The CDK4\/6 inhibitor revolution \u2014 a game-changing era for breast cancer treatment. Nat Rev Clin Oncol. 2023;21:89\u2013105. https:\/\/doi.org\/10.1038\/s41571-023-00840-4.","journal-title":"Nat Rev Clin Oncol"},{"key":"3725_CR13","doi-asserted-by":"publisher","DOI":"10.1200\/PO.18.00383","author":"J Peguero","year":"2019","unstructured":"Peguero J, Sohal DPS, Neil O BH, et al. Tissue\/Site-Agnostic Study of Ribociclib for Tumors With Cyclin D\u2013CDK4\/6 Pathway Genomic Alterations: A Phase II, Open-Label, Single-Arm Basket Study. JCO Precis Oncol. 2019. https:\/\/doi.org\/10.1200\/PO.18.00383.","journal-title":"JCO Precis Oncol"},{"key":"3725_CR14","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s11060-020-03641-2","volume":"149","author":"M DeWire","year":"2020","unstructured":"DeWire M, Fuller C, Hummel TR, et al. A phase I\/II study of ribociclib following radiation therapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG). J Neurooncol. 2020;149:511\u201322. https:\/\/doi.org\/10.1007\/s11060-020-03641-2.","journal-title":"J Neurooncol"},{"key":"3725_CR15","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1016\/j.ccell.2024.08.006","volume":"42","author":"I Liu","year":"2024","unstructured":"Liu I, Alencastro Veiga Cruzeiro G, Bjerke L, et al. GABAergic neuronal lineage development determines clinically actionable targets in diffuse hemispheric glioma, H3G34-mutant. Cancer Cell. 2024;42:1528\u2013e154817. https:\/\/doi.org\/10.1016\/j.ccell.2024.08.006.","journal-title":"Cancer Cell"},{"key":"3725_CR16","doi-asserted-by":"publisher","first-page":"5777","DOI":"10.1158\/1078-0432.CCR-19-0133","volume":"25","author":"A-C Tien","year":"2019","unstructured":"Tien A-C, Li J, Bao X, et al. A Phase 0 Trial of Ribociclib in Recurrent Glioblastoma Patients Incorporating a Tumor Pharmacodynamic- and Pharmacokinetic-Guided Expansion Cohort. Clin Cancer Res. 2019;25:5777\u201386. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-0133.","journal-title":"Clin Cancer Res"},{"key":"3725_CR17","doi-asserted-by":"publisher","first-page":"D941","DOI":"10.1093\/nar\/gky1015","volume":"47","author":"JG Tate","year":"2019","unstructured":"Tate JG, Bamford S, Jubb HC, et al. COSMIC: the Catalogue Of Somatic Mutations In Cancer. Nucleic Acids Res. 2019;47:D941\u20137. https:\/\/doi.org\/10.1093\/nar\/gky1015.","journal-title":"Nucleic Acids Res"},{"key":"3725_CR18","doi-asserted-by":"publisher","first-page":"114095","DOI":"10.18632\/oncotarget.23125","volume":"8","author":"L Mayr","year":"2017","unstructured":"Mayr L, Pirker C, L\u00f6tsch D, et al. CD44 drives aggressiveness and chemoresistance of a metastatic human osteosarcoma xenograft model. Oncotarget. 2017;8:114095\u2013108. https:\/\/doi.org\/10.18632\/oncotarget.23125.","journal-title":"Oncotarget"},{"key":"3725_CR19","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s00401-021-02327-x","volume":"142","author":"D L\u00f6tsch","year":"2021","unstructured":"L\u00f6tsch D, Kirchhofer D, Englinger B, et al. Targeting fibroblast growth factor receptors to combat aggressive ependymoma. Acta Neuropathol. 2021;142:339\u201360. https:\/\/doi.org\/10.1007\/s00401-021-02327-x.","journal-title":"Acta Neuropathol"},{"key":"3725_CR20","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1038\/nprot.2014.158","volume":"9","author":"MA Lancaster","year":"2014","unstructured":"Lancaster MA, Knoblich JA. Generation of cerebral organoids from human pluripotent stem cells. Nat Protoc. 2014;9:2329\u201340. https:\/\/doi.org\/10.1038\/nprot.2014.158.","journal-title":"Nat Protoc"},{"key":"3725_CR21","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1038\/sj.bjc.6605642","volume":"102","author":"P Workman","year":"2010","unstructured":"Workman P, Aboagye EO, Balkwill F, et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer. 2010;102:1555\u201377. https:\/\/doi.org\/10.1038\/sj.bjc.6605642.","journal-title":"Br J Cancer"},{"key":"3725_CR22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00401-024-02842-7","volume":"149","author":"S Madlener","year":"2025","unstructured":"Madlener S, Stepien N, Senfter D, et al. Detection of H3F3A K27M or BRAF V600E in liquid biopsies of brain tumor patients as diagnostic and monitoring biomarker: impact of tumor localization and sampling method. Acta Neuropathol. 2025;149:5. https:\/\/doi.org\/10.1007\/s00401-024-02842-7.","journal-title":"Acta Neuropathol"},{"key":"3725_CR23","unstructured":"Michigan Center for Translational Pathology. Available from: https:\/\/www.pathology.med.umich.edu\/mctp\/mi-oncoseq-study.\u00a0Cited 24 Oct 2024."},{"key":"3725_CR24","doi-asserted-by":"publisher","first-page":"6197","DOI":"10.1158\/1078-0432.CCR-21-2660","volume":"27","author":"KC Schreck","year":"2021","unstructured":"Schreck KC, Morin A, Zhao G, et al. Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAF-Mutant Human Glioma. Clin Cancer Res. 2021;27:6197\u2013208. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-2660.","journal-title":"Clin Cancer Res"},{"key":"3725_CR25","doi-asserted-by":"publisher","first-page":"102183","DOI":"10.1016\/j.xcrm.2025.102183","volume":"6","author":"YL Xing","year":"2025","unstructured":"Xing YL, Panovska D, Park J-W, et al. BRAF\/MEK inhibition induces cell state transitions boosting immune checkpoint sensitivity in BRAF-mutant glioma. Cell Rep Med. 2025;6:102183. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102183.","journal-title":"Cell Rep Med"},{"key":"3725_CR26","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41587-020-0439-x","volume":"38","author":"PA Ewels","year":"2020","unstructured":"Ewels PA, Peltzer A, Fillinger S, et al. The nf-core framework for community-curated bioinformatics pipelines. Nat Biotechnol. 2020;38:276\u20138. https:\/\/doi.org\/10.1038\/s41587-020-0439-x.","journal-title":"Nat Biotechnol"},{"key":"3725_CR27","doi-asserted-by":"publisher","unstructured":"Patel H, Manning J, Ewels P et al. nf-core\/rnaseq: nf-core\/rnaseq v3.21.0 - Mercury Macaw. 2025. https:\/\/doi.org\/10.5281\/zenodo.17153746.","DOI":"10.5281\/zenodo.17153746"},{"key":"3725_CR28","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41467-017-02391-6","volume":"9","author":"M Schubert","year":"2018","unstructured":"Schubert M, Klinger B, Kl\u00fcnemann M, et al. Perturbation-response genes reveal signaling footprints in cancer gene expression. Nat Commun. 2018;9:20. https:\/\/doi.org\/10.1038\/s41467-017-02391-6.","journal-title":"Nat Commun"},{"key":"3725_CR29","doi-asserted-by":"publisher","first-page":"e47825","DOI":"10.1371\/journal.pone.0047825","volume":"7","author":"P Ruggieri","year":"2012","unstructured":"Ruggieri P, Mangino G, Fioretti B, et al. The inhibition of KCa3.1 channels activity reduces cell motility in glioblastoma derived cancer stem cells. PLoS ONE. 2012;7:e47825. https:\/\/doi.org\/10.1371\/journal.pone.0047825.","journal-title":"PLoS ONE"},{"key":"3725_CR30","doi-asserted-by":"publisher","first-page":"167950","DOI":"10.1016\/j.bbadis.2025.167950","volume":"1871","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Ribas HT, Winnischofer SMB, et al. Targeting Ca-activated K channels in glioma. Biochim Biophys Acta Mol Basis Dis. 2025;1871:167950. https:\/\/doi.org\/10.1016\/j.bbadis.2025.167950.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"3725_CR31","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s00726-010-0729-6","volume":"40","author":"YH Kang","year":"2011","unstructured":"Kang YH, Ji NY, Lee C, Il, et al. ESM-1 silencing decreased cell survival, migration, and invasion and modulated cell cycle progression in hepatocellular carcinoma. Amino Acids. 2011;40:1003\u201313. https:\/\/doi.org\/10.1007\/s00726-010-0729-6.","journal-title":"Amino Acids"},{"key":"3725_CR32","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.canlet.2015.01.010","volume":"359","author":"JV Joseph","year":"2015","unstructured":"Joseph JV, Conroy S, Pavlov K, et al. Hypoxia enhances migration and invasion in glioblastoma by promoting a mesenchymal shift mediated by the HIF1\u03b1-ZEB1 axis. Cancer Lett. 2015;359:107\u201316. https:\/\/doi.org\/10.1016\/j.canlet.2015.01.010.","journal-title":"Cancer Lett"},{"key":"3725_CR33","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1200\/JCO.2014.58.3922","volume":"33","author":"M Mistry","year":"2015","unstructured":"Mistry M, Zhukova N, Merico D, et al. BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. J Clin Oncol. 2015;33:1015\u201322. https:\/\/doi.org\/10.1200\/JCO.2014.58.3922.","journal-title":"J Clin Oncol"},{"key":"3725_CR34","doi-asserted-by":"publisher","first-page":"2876","DOI":"10.1158\/1535-7163.MCT-08-0431","volume":"7","author":"KSM Smalley","year":"2008","unstructured":"Smalley KSM, Lioni M, Dalla Palma M, et al. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther. 2008;7:2876\u201383. https:\/\/doi.org\/10.1158\/1535-7163.MCT-08-0431.","journal-title":"Mol Cancer Ther"},{"key":"3725_CR35","doi-asserted-by":"publisher","first-page":"4868","DOI":"10.1158\/1078-0432.CCR-13-0827","volume":"19","author":"KL Nathanson","year":"2013","unstructured":"Nathanson KL, Martin A-M, Wubbenhorst B, et al. Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Res. 2013;19:4868\u201378. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-0827.","journal-title":"Clin Cancer Res"},{"key":"3725_CR36","doi-asserted-by":"publisher","first-page":"100788","DOI":"10.1016\/j.esmoop.2023.100788","volume":"8","author":"MA Gouda","year":"2023","unstructured":"Gouda MA, Subbiah V. Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy. ESMO Open. 2023;8:100788. https:\/\/doi.org\/10.1016\/j.esmoop.2023.100788.","journal-title":"ESMO Open"},{"key":"3725_CR37","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.radonc.2015.06.026","volume":"117","author":"U Schick","year":"2015","unstructured":"Schick U, Kyula J, Barker H, et al. Trametinib radiosensitises RAS- and BRAF-mutated melanoma by perturbing cell cycle and inducing senescence. Radiother Oncol. 2015;117:364\u201375. https:\/\/doi.org\/10.1016\/j.radonc.2015.06.026.","journal-title":"Radiother Oncol"},{"key":"3725_CR38","doi-asserted-by":"publisher","unstructured":"Santander Ballest\u00edn S, Abad\u00eda Labena M, Avedillo-Salas A, et al. Advances in CDK4 and 6 Inhibitors: Transforming Breast Cancer Treatment. Cancers (Basel). 2025;17. https:\/\/doi.org\/10.3390\/cancers17050760.","DOI":"10.3390\/cancers17050760"},{"key":"3725_CR39","doi-asserted-by":"publisher","first-page":"6","DOI":"10.20517\/cdr.2024.125","volume":"8","author":"B Biersack","year":"2025","unstructured":"Biersack B, Nitzsche B, H\u00f6pfner M. Histone deacetylases in the regulation of cell death and survival mechanisms in resistant BRAF-mutant cancers. Cancer Drug Resist. 2025;8:6. https:\/\/doi.org\/10.20517\/cdr.2024.125.","journal-title":"Cancer Drug Resist"},{"key":"3725_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms15208","volume":"8","author":"YH Kim","year":"2017","unstructured":"Kim YH, Choi YW, Lee J, et al. Senescent tumor cells lead the collective invasion in thyroid cancer. Nat Commun. 2017;8:1\u201314. https:\/\/doi.org\/10.1038\/ncomms15208.","journal-title":"Nat Commun"},{"key":"3725_CR41","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nature25167","volume":"553","author":"M Milanovic","year":"2018","unstructured":"Milanovic M, Fan DNY, Belenki D, et al. Senescence-associated reprogramming promotes cancer stemness. Nature. 2018;553:96\u2013100. https:\/\/doi.org\/10.1038\/nature25167.","journal-title":"Nature"},{"key":"3725_CR42","doi-asserted-by":"publisher","first-page":"350","DOI":"10.3109\/07357900903286966","volume":"28","author":"J Li","year":"2010","unstructured":"Li J, Xu M, Yang Z, et al. Simultaneous inhibition of MEK and CDK4 leads to potent apoptosis in human melanoma cells. Cancer Invest. 2010;28:350\u20136. https:\/\/doi.org\/10.3109\/07357900903286966.","journal-title":"Cancer Invest"},{"key":"3725_CR43","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1038\/nm.2941","volume":"18","author":"LN Kwong","year":"2012","unstructured":"Kwong LN, Costello JC, Liu H, et al. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med. 2012;18:1503\u201310. https:\/\/doi.org\/10.1038\/nm.2941.","journal-title":"Nat Med"},{"key":"3725_CR44","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1002\/ijc.31220","volume":"142","author":"CA Martin","year":"2018","unstructured":"Martin CA, Cullinane C, Kirby L, et al. Palbociclib synergizes with BRAF and MEK inhibitors in treatment na\u00efve melanoma but not after the development of BRAF inhibitor resistance. Int J Cancer. 2018;142:2139\u201352. https:\/\/doi.org\/10.1002\/ijc.31220.","journal-title":"Int J Cancer"},{"key":"3725_CR45","doi-asserted-by":"publisher","first-page":"5455","DOI":"10.1158\/0008-5472.CAN-15-3384","volume":"76","author":"JLF Teh","year":"2016","unstructured":"Teh JLF, Purwin TJ, Greenawalt EJ, et al. An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4\/6 Inhibitor-Based Therapies in Melanoma. Cancer Res. 2016;76:5455\u201366. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-3384.","journal-title":"Cancer Res"},{"key":"3725_CR46","doi-asserted-by":"publisher","first-page":"1031378","DOI":"10.3389\/fonc.2022.1031378","volume":"12","author":"R Lehmann","year":"2022","unstructured":"Lehmann R, Rayner BS, Ziegler DS. Resistance mechanisms in BRAFV600E paediatric high-grade glioma and current therapeutic approaches. Front Oncol. 2022;12:1031378. https:\/\/doi.org\/10.3389\/fonc.2022.1031378.","journal-title":"Front Oncol"},{"key":"3725_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.02.018","author":"L Mayr","year":"2025","unstructured":"Mayr L, Neyazi S, Schwark K, et al. Effective targeting of PDGFRA-altered high-grade glioma with avapritinib. Cancer Cell. 2025. https:\/\/doi.org\/10.1016\/j.ccell.2025.02.018.","journal-title":"Cancer Cell"},{"key":"3725_CR48","doi-asserted-by":"publisher","first-page":"5590","DOI":"10.1038\/s41388-021-01911-5","volume":"40","author":"B Wang","year":"2021","unstructured":"Wang B, Zhang W, Zhang G, et al. Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma. Oncogene. 2021;40:5590\u20139. https:\/\/doi.org\/10.1038\/s41388-021-01911-5.","journal-title":"Oncogene"},{"key":"3725_CR49","doi-asserted-by":"publisher","first-page":"39595","DOI":"10.18632\/oncotarget.9153","volume":"7","author":"MS Lee","year":"2016","unstructured":"Lee MS, Helms TL, Feng N, et al. Efficacy of the combination of MEK and CDK4\/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models. Oncotarget. 2016;7:39595\u2013608. https:\/\/doi.org\/10.18632\/oncotarget.9153.","journal-title":"Oncotarget"},{"key":"3725_CR50","doi-asserted-by":"publisher","unstructured":"Zhao Y, Kang J-H, Yoo K-C, et al. K-RAS Acts as a Critical Regulator of CD44 to Promote the Invasiveness and Stemness of GBM in Response to Ionizing Radiation. Int J Mol Sci. 2021;22. https:\/\/doi.org\/10.3390\/ijms222010923.","DOI":"10.3390\/ijms222010923"},{"key":"3725_CR51","doi-asserted-by":"crossref","unstructured":"Sussman JH, Oldridge DA, Yu W, et al. A longitudinal single-cell and spatial multiomic. atlas of pediatric high-grade glioma; 2024.","DOI":"10.1101\/2024.03.06.583588"},{"key":"3725_CR52","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1002\/cam4.4506","volume":"11","author":"HP Weitzenb\u00f6ck","year":"2022","unstructured":"Weitzenb\u00f6ck HP, Gschwendtner A, Wiesner C, et al. Proteome analysis of NRF2 inhibition in melanoma reveals CD44. Cancer Med. 2022;11:956\u201367. https:\/\/doi.org\/10.1002\/cam4.4506.","journal-title":"Cancer Med"},{"key":"3725_CR53","doi-asserted-by":"crossref","unstructured":"De Miglio MR, Ni K, Mohammed S, Bezerra DP. Reviews in Breast Cancer: 2023. Frontiers Media SA; 2024.","DOI":"10.3389\/978-2-8325-5609-2"},{"key":"3725_CR54","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1158\/1078-0432.CCR-21-3872","volume":"28","author":"M Schuler","year":"2022","unstructured":"Schuler M, Zimmer L, Kim KB, et al. Phase Ib\/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma. Clin Cancer Res. 2022;28:3002\u201310. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3872.","journal-title":"Clin Cancer Res"},{"key":"3725_CR55","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1093\/annonc\/mdu482","volume":"26","author":"AW Tolcher","year":"2015","unstructured":"Tolcher AW, Bendell JC, Papadopoulos KP, et al. A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors. Ann Oncol. 2015;26:58\u201364. https:\/\/doi.org\/10.1093\/annonc\/mdu482.","journal-title":"Ann Oncol"},{"key":"3725_CR56","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/cncr.31044","volume":"124","author":"PL B\u00e9dard","year":"2018","unstructured":"B\u00e9dard PL, Davies MA, Kopetz S, et al. First-in-human trial of the PI3K\u03b2-selective inhibitor SAR260301 in patients with advanced solid tumors. Cancer. 2018;124:315\u201324. https:\/\/doi.org\/10.1002\/cncr.31044.","journal-title":"Cancer"},{"key":"3725_CR57","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1007\/s10637-016-0377-0","volume":"34","author":"JE Grilley-Olson","year":"2016","unstructured":"Grilley-Olson JE, Bedard PL, Fasolo A, et al. A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K\/mTOR inhibitor GSK2126458 in patients with advanced solid tumors. Invest New Drugs. 2016;34:740\u20139. https:\/\/doi.org\/10.1007\/s10637-016-0377-0.","journal-title":"Invest New Drugs"},{"key":"3725_CR58","doi-asserted-by":"publisher","unstructured":"Marques Da Costa ME, Zaidi S, Scoazec J-Y, et al (2023) A biobank of pediatric patient-derived-xenograft models in cancer precision medicine trial MAPPYACTS for relapsed and refractory tumors. Commun Biol 6:949. https:\/\/doi.org\/10.1038\/s42003-023-05320-0.","DOI":"10.1038\/s42003-023-05320-0"},{"key":"3725_CR59","doi-asserted-by":"publisher","unstructured":"Tan X-L, Le A, Lam FC, et al (2022) Current Treatment Approaches and Global Consensus Guidelines for Brain Metastases in Melanoma. Front Oncol 12: https:\/\/doi.org\/10.3389\/fonc.2022.885472.","DOI":"10.3389\/fonc.2022.885472"},{"key":"3725_CR60","doi-asserted-by":"publisher","unstructured":"Johnson A, Severson E, Gay L, et al (2017) Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures. Oncologist 22:1478\u20131490. https:\/\/doi.org\/10.1634\/theoncologist.2017-0242.","DOI":"10.1634\/theoncologist.2017-0242"},{"key":"3725_CR61","doi-asserted-by":"publisher","unstructured":"Kappel C, Elliott MJ, Kumar V, et al (2024) Comparative overall survival of CDK4\/6 inhibitors in combination with endocrine therapy in advanced breast cancer. Sci Rep 14:3129. https:\/\/doi.org\/10.1038\/s41598-024-53151-8.","DOI":"10.1038\/s41598-024-53151-8"},{"key":"3725_CR62","doi-asserted-by":"publisher","unstructured":"Patel RR, Ramkissoon SH, Ross J, Weintraub L (2020) Tumor mutational burden and driver mutations: Characterizing the genomic landscape of pediatric brain tumors. Pediatr Blood Cancer 67. https:\/\/doi.org\/10.1002\/pbc.28338.","DOI":"10.1002\/pbc.28338"},{"key":"3725_CR63","doi-asserted-by":"publisher","unstructured":"Sha D, Jin Z, Budczies J, et al (2020) Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors. Cancer Discov 10:1808\u20131825. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0522.","DOI":"10.1158\/2159-8290.CD-20-0522"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-026-03725-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03725-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03725-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:03:37Z","timestamp":1783605817000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-026-03725-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,16]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3725"],"URL":"https:\/\/doi.org\/10.1186\/s13046-026-03725-3","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,16]]},"assertion":[{"value":"28 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the Medical University of Vienna (Date 30.05.2023\/No 1244\/2016). GZ 2024\u2009\u2212\u20090.901.338 of the Medical University of Vienna and Austrian Ministry for Science and Technology (subcutaneous mouse model), G23\/036 of the Regierungspr\u00e4sidium Freiburg im Breisgau (orthotopic mouse model).Informed consent was obtained from all individual participants or the parents included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication was obtained from all individual participants or the parents included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"J.G. is consultant, advisory board participant and received honoraria for Novartis, Roche, Rhythm Pharmaceuticals, and Ipsen (not relevant to this study).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"154"}}